Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering therapies designed to treat immune-mediated and metabolic diseases. The Company's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļALDX
āļāļ·āđāļāļāļĢāļīāļĐāļąāļAldeyra Therapeutics Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļMay 02, 2014
āļāļĩāļāļĩāđāļBrady (Todd C)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ9
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļMay 02
āļāļĩāđāļāļĒāļđāđ131 Hartwell Avenue
āđāļĄāļ·āļāļLEXINGTON
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ02421
āđāļāļĢāļĻāļąāļāļāđ17817614904
āđāļ§āđāļāđāļāļāđhttps://www.aldeyra.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļALDX
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļMay 02, 2014
āļāļĩāļāļĩāđāļBrady (Todd C)
Dr. Todd C. Brady, M.D., Ph.D.
Dr. Todd C. Brady, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
Mr. Martin J. Joyce
Independent Director
Dr. Gary M. Phillips, M.D.
Dr. Gary M. Phillips, M.D.
Independent Director
Dr. Ben R. Bronstein, M.D.
Dr. Ben R. Bronstein, M.D.
Independent Director
Dr. Neal S. Walker
Independent Director
Dr. Stephen G. Machatha, Ph.D.
Dr. Stephen G. Machatha, Ph.D.
Chief Development Officer
Chief Development Officer
Ms. Nancy B. Miller-Rich
Independent Director
Mr. Michael (Mike) Alfieri
Mr. Michael (Mike) Alfieri
Principal Financial Officer and Principal Accounting Officer
Principal Financial Officer and Principal Accounting Officer
Mr. William D. (Chip) Clark
Mr. William D. (Chip) Clark
Independent Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Dr. Todd C. Brady, M.D., Ph.D.
Dr. Todd C. Brady, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
Mr. Martin J. Joyce
Independent Director
Dr. Gary M. Phillips, M.D.
Dr. Gary M. Phillips, M.D.
Independent Director
Dr. Ben R. Bronstein, M.D.
Dr. Ben R. Bronstein, M.D.
Independent Director
Dr. Neal S. Walker
Independent Director